Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PTB-01
- Development stage
- Preclinical
- Lead developer
- Next Innovative Therapeutics
- Administration
- Oral
01
Overview
PTB-01 (also known as PBTX-01) is a nutraceutical candidate developed by Next Innovative Therapeutics (NINTx) for newborn gastrointestinal health. It is designed to support digestive and gut health in newborns by modulating biological pathways directly and indirectly through the gut microbiome. PTB-01 is developed using NINTx's proprietary GAIApath® and xGIbiomics® platforms, which leverage data analytics and in vitro gastrointestinal models to identify and validate natural products from Brazilian biodiversity.
- Other names
- PBTX-01PBTX01PBTX 01
Beyond the preview
Go deeper on PTB-01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PTB-01.